Literature DB >> 4813080

Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses.

P Kremers, J Duvivier, C Heusghem.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4813080     DOI： 10.1002/j.1552-4604.1974.tb02300.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  25 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions.

Authors:  M A Kielhofner
Journal:  Tex Heart Inst J       Date:  1990

3.  Bacterial infection imaging with [18F]fluoropropyl-trimethoprim.

Authors:  Mark A Sellmyer; Iljung Lee; Catherine Hou; Chi-Chang Weng; Shihong Li; Brian P Lieberman; Chenbo Zeng; David A Mankoff; Robert H Mach
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

4.  Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

Authors:  P G Hoggard; S Kewn; M G Barry; S H Khoo; D J Back
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  General survey of trimethoprim combinations in the treatment of urinary tract infections.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1979       Impact factor: 3.553

6.  Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children.

Authors:  Elizabeth J Thompson; Huali Wu; Anil Maharaj; Andrea N Edginton; Stephen J Balevic; Marjan Cobbaert; Anthony P Cunningham; Christoph P Hornik; Michael Cohen-Wolkowiez
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 7.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

8.  Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis.

Authors:  Allen C Cheng; Emma S McBryde; Vanaporn Wuthiekanun; Wirongrong Chierakul; Premjit Amornchai; Nicholas P J Day; Nicholas J White; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

9.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

10.  Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods.

Authors:  B Odlind; P Hartvig; K E Fjellström; B Lindström; S Bengtsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.